Literature DB >> 2432836

Suramin in the treatment of AIDS: mechanism of action.

E De Clercq.   

Abstract

Suramin is a potent inhibitor of the reverse transcriptase (RNA-directed DNA polymerase) of retroviruses, including the HTLV-III/LAV (human T-cell lymphotropic virus type III/lymphadenopathy-associated virus) reverse transcriptase. Although suramin is far from specific as a reverse transcriptase inhibitor and known to interact with a multitude of proteins and enzymes, it is able to suppress the replication and cytopathic effect of HTLV-III/LAV at concentrations which are nontoxic for the host cells and readily attainable in humans. Consequently, suramin is also able to block HTLV-III/LAV replication in patients. The mechanism of action of suramin at the molecular biological level, its mode of transport and accumulation by the infected host cells, and the bases for its rather selective virustatic activity remain, to a large extent, to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2432836     DOI: 10.1016/0166-3542(87)90034-9

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  17 in total

1.  Enzymatic kinetic studies with the non-nucleoside HIV reverse transcriptase inhibitor U-9843.

Authors:  I W Althaus; R J LeMay; A J Gonzales; M R Deibel; S K Sharma; F J Kezdy; L Resnick; M E Busso; P A Aristoff; F Reusser
Journal:  Experientia       Date:  1992-12-01

Review 2.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

3.  Suramin and NF449 are IP5K inhibitors that disrupt inositol hexakisphosphate-mediated regulation of cullin-RING ligase and sensitize cancer cells to MLN4924/pevonedistat.

Authors:  Xiaozhe Zhang; Shaodong Shi; Yang Su; Xiaoli Yang; Sining He; Xiuyan Yang; Jing Wu; Jian Zhang; Feng Rao
Journal:  J Biol Chem       Date:  2020-06-03       Impact factor: 5.157

4.  Comparison of inhibitory activities of various antiretroviral agents against particle-derived and recombinant human immunodeficiency virus type 1 reverse transcriptases.

Authors:  R F Schinazi; B F Eriksson; S H Hughes
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

5.  A high-throughput screening campaign to identify inhibitors of DXP reductoisomerase (IspC) and MEP cytidylyltransferase (IspD).

Authors:  Amanda Haymond; Tyrone Dowdy; Chinchu Johny; Claire Johnson; Haley Ball; Allyson Dailey; Brandon Schweibenz; Karen Villarroel; Richard Young; Clark J Mantooth; Trishal Patel; Jessica Bases; Cynthia S Dowd; Robin D Couch
Journal:  Anal Biochem       Date:  2017-11-24       Impact factor: 3.365

6.  Illimaquinone, a selective inhibitor of the RNase H activity of human immunodeficiency virus type 1 reverse transcriptase.

Authors:  S Loya; R Tal; Y Kashman; A Hizi
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

7.  Influence of suramin on the expression of Fc receptors and other markers on human monocytes and U937 cells, and on their phagocytic properties.

Authors:  C Schiller; A Spittler; M Willheim; Z Szépfalusi; H Agis; M Köller; M Peterlik; G Boltz-Nitulescu
Journal:  Immunology       Date:  1994-04       Impact factor: 7.397

Review 8.  Zidovudine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  H D Langtry; D M Campoli-Richards
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

9.  P2X-selective purinergic antagonists are strong inhibitors of HIV-1 fusion during both cell-to-cell and cell-free infection.

Authors:  Talia H Swartz; Anthony M Esposito; Natasha D Durham; Boris M Hartmann; Benjamin K Chen
Journal:  J Virol       Date:  2014-07-16       Impact factor: 5.103

10.  Proteoglycans act as cellular hepatitis delta virus attachment receptors.

Authors:  Oscar Lamas Longarela; Tobias T Schmidt; Katrin Schöneweis; Raffaella Romeo; Heiner Wedemeyer; Stephan Urban; Andreas Schulze
Journal:  PLoS One       Date:  2013-03-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.